FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2561676411> ?p ?o ?g. }

• W2561676411 endingPage "5476" @default.
• W2561676411 startingPage "5476" @default.
• W2561676411 abstract "Abstract Introduction and aim. Relapse following allogeneic hematopoietic stem cell transplantation (HSCT) is a major cause of treatment failure and is associated with a poor prognosis. Overall survivals are around 50% at 5 years following allogeneic HSCT in intermediate and high risk AML. Survivals remain less than 20% in poor-risk and very poor-risk patients based on the cytogenetic profile. Thus, prevention of relapse following allogeneic HSCT remains an unmet clinical need. Low-dose azacitidine maintenance post-HSCT has been shown to augment graft-versus-leukemia effect and may prolong survivals. We aim to prospectively evaluate the effect of azacitidine maintenance following allogeneic HSCT in high risk AML and MDS. Method. Consecutive patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in remission following first allogeneic HSCT or second allogeneic HSCT (from the original donor) were recruited. High risk AML in this study comprised patients with poor risk karyotype, secondary AML transformed from underlying MDS, presence of fms-like tyrosine kinase 3-internal tandem duplication (FLT3 -ITD) and non-remission before HSCT. Azacitidine was administered at 100mg daily for 3 days per cycle every 28 days until progression or a maximum of 8 cycles. The clinicopathologic and treatment characteristics were determined. The occurrence of graft-versus-host disease (GVHD) was determined. DNA chimerism was determined in the bone marrow before the initiation of azacitidine, after 4th and 8th cycles of azacitidine and at 1 year. DNA chimerism was determined by quantification of polymorphic short tandem repeat sequences. The progression-free survival (PFS) and overall survival (OS) were determined by Kaplan-Meier analysis. Results. Thirty-four patients with high-risk AML (N=31) and MDS (N=3) were recruited. The median duration of follow-up was 14 months (range: 2 - 44 months). Twenty-two patients received azacitidine maintenance after first allogeneic HSCT, whereas 12 patients received azacitidine maintenance after a second allogeneic HSCT from the same donor following relapse from a first allogeneic HSCT For patients receiving azacitidine after first HSCT, at a median follow-up of 18.5 months (range: 5- 36 months), the median PFS was not reached, and the median OS was 32 months (95% confidence interval [C.I.]: 24.85-39.15). The 24-month PFS and OS were 66.1% and 73.2% respectively. Acute and chronic GVHD occurred in 7 (31.8%) and 17 patients (77%). For patients receiving azacitidine after second HSCT, at a median follow-up of 14 months (range: 9 - 46 months), the median PFS and OS were 9 months (95% C.I.:6.94-11.04) and 14 months (range: 11.77 - 16.23 months). The 24-month PFS and OS were 25% and 14% respectively. Acute and chronic GVHD occurred in 1 (8.3%) and 5 (41.7%) patients respectively. In both groups, 100% donor chimerism was achieved during azacitidine maintenance. Conclusion. Azacitidine maintenance following first allogeneic HSCT resulted in favorable 2-year survivals in selected patients with high-risk AML and MDS. Nevertheless, survivals were poor despite azacitidine maintenance after second allogeneic HSCT from the same donor. Full donor chimerism was maintained during azacitidine maintenance. Disclosures No relevant conflicts of interest to declare." @default.
• W2561676411 created "2017-01-06" @default.
• W2561676411 creator A5018753809 @default.
• W2561676411 creator A5019661617 @default.
• W2561676411 creator A5038966850 @default.
• W2561676411 creator A5082583465 @default.
• W2561676411 date "2015-12-03" @default.
• W2561676411 modified "2023-10-14" @default.
• W2561676411 title "Prospective Evaluation of Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome" @default.
• W2561676411 doi "https://doi.org/10.1182/blood.v126.23.5476.5476" @default.
• W2561676411 hasPublicationYear "2015" @default.
• W2561676411 type Work @default.
• W2561676411 sameAs 2561676411 @default.
• W2561676411 citedByCount "2" @default.
• W2561676411 countsByYear W25616764112016 @default.
• W2561676411 countsByYear W25616764112021 @default.
• W2561676411 crossrefType "journal-article" @default.
• W2561676411 hasAuthorship W2561676411A5018753809 @default.
• W2561676411 hasAuthorship W2561676411A5019661617 @default.
• W2561676411 hasAuthorship W2561676411A5038966850 @default.
• W2561676411 hasAuthorship W2561676411A5082583465 @default.
• W2561676411 hasConcept C104317684 @default.
• W2561676411 hasConcept C126322002 @default.
• W2561676411 hasConcept C143998085 @default.
• W2561676411 hasConcept C150194340 @default.
• W2561676411 hasConcept C190727270 @default.
• W2561676411 hasConcept C203014093 @default.
• W2561676411 hasConcept C2776239401 @default.
• W2561676411 hasConcept C2777408962 @default.
• W2561676411 hasConcept C2778461978 @default.
• W2561676411 hasConcept C2778729363 @default.
• W2561676411 hasConcept C2780007613 @default.
• W2561676411 hasConcept C2780817109 @default.
• W2561676411 hasConcept C2911091166 @default.
• W2561676411 hasConcept C55493867 @default.
• W2561676411 hasConcept C71924100 @default.
• W2561676411 hasConcept C86803240 @default.
• W2561676411 hasConceptScore W2561676411C104317684 @default.
• W2561676411 hasConceptScore W2561676411C126322002 @default.
• W2561676411 hasConceptScore W2561676411C143998085 @default.
• W2561676411 hasConceptScore W2561676411C150194340 @default.
• W2561676411 hasConceptScore W2561676411C190727270 @default.
• W2561676411 hasConceptScore W2561676411C203014093 @default.
• W2561676411 hasConceptScore W2561676411C2776239401 @default.
• W2561676411 hasConceptScore W2561676411C2777408962 @default.
• W2561676411 hasConceptScore W2561676411C2778461978 @default.
• W2561676411 hasConceptScore W2561676411C2778729363 @default.
• W2561676411 hasConceptScore W2561676411C2780007613 @default.
• W2561676411 hasConceptScore W2561676411C2780817109 @default.
• W2561676411 hasConceptScore W2561676411C2911091166 @default.
• W2561676411 hasConceptScore W2561676411C55493867 @default.
• W2561676411 hasConceptScore W2561676411C71924100 @default.
• W2561676411 hasConceptScore W2561676411C86803240 @default.
• W2561676411 hasIssue "23" @default.
• W2561676411 hasLocation W25616764111 @default.
• W2561676411 hasOpenAccess W2561676411 @default.
• W2561676411 hasPrimaryLocation W25616764111 @default.
• W2561676411 hasRelatedWork W2117738066 @default.
• W2561676411 hasRelatedWork W2315268119 @default.
• W2561676411 hasRelatedWork W2319910057 @default.
• W2561676411 hasRelatedWork W2404178125 @default.
• W2561676411 hasRelatedWork W2564979848 @default.
• W2561676411 hasRelatedWork W2889487602 @default.
• W2561676411 hasRelatedWork W2911369452 @default.
• W2561676411 hasRelatedWork W2936525421 @default.
• W2561676411 hasRelatedWork W4286817035 @default.
• W2561676411 hasRelatedWork W4313260741 @default.
• W2561676411 hasVolume "126" @default.
• W2561676411 isParatext "false" @default.
• W2561676411 isRetracted "false" @default.
• W2561676411 magId "2561676411" @default.
• W2561676411 workType "article" @default.